170 related articles for article (PubMed ID: 2480490)
1. Chronic therapy of severe heart failure with enoximone.
Gilfrich HJ; Witzke-Gross J; Römer A
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S75-7. PubMed ID: 2480490
[TBL] [Abstract][Full Text] [Related]
2. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Weber KT; Janicki JS; Jain MC
J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
[TBL] [Abstract][Full Text] [Related]
3. Long-term enoximone therapy in unstable chronic heart failure.
Treese N; Rhein S; Erbel R; Meyer J
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S78-83. PubMed ID: 2480491
[TBL] [Abstract][Full Text] [Related]
4. [Effect of oral long-term enoximone therapy on the arrhythmia profile in chronic heart failure].
Treese N; Rhein S; Werneyer A; Erbel R; von Olshausen K; Pop T; Meyer J
Z Kardiol; 1988 Oct; 77(10):653-9. PubMed ID: 2467449
[TBL] [Abstract][Full Text] [Related]
5. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
Uretsky BF; Valdes AM; Reddy PS
Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
[TBL] [Abstract][Full Text] [Related]
6. [Enoximone/dobutamine comparison in chronic congestive cardiac insufficiency with low cardiac output].
Galinier M; Rochiccioli JP; Edouard P; Fourcade J; Massabuau P; Puel J; Fauvel JM; Bounhoure JP
Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():27-32. PubMed ID: 2147831
[TBL] [Abstract][Full Text] [Related]
7. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
Petein M; Levine TB; Cohn JN
Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
[TBL] [Abstract][Full Text] [Related]
8. The role of novel inotropic agents in the treatment of heart failure.
LeJemtel TH; Keren G; Reis D; Sonnenblick EH
J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S47-54. PubMed ID: 2433542
[TBL] [Abstract][Full Text] [Related]
9. Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors.
Lee HR; Hershberger RE; Port JD; Rasmussen R; Renlund DG; O'Connell JB; Gilbert EM; Mealey PC; Volkman K; Menlove R
J Thorac Cardiovasc Surg; 1991 Aug; 102(2):246-58. PubMed ID: 1650867
[TBL] [Abstract][Full Text] [Related]
10. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure.
Bader FM; Gilbert EM; Mehta NA; Bristow MR
Congest Heart Fail; 2010; 16(6):265-70. PubMed ID: 21091611
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiologic effects of enoximone in patients with congestive heart failure.
Hohnloser SH; Zehender M; Geibel A; Meinertz T; Just H
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S29-32. PubMed ID: 2480482
[TBL] [Abstract][Full Text] [Related]
12. [Enoximone and ventricular arrhythmia in chronic heart failure].
Treese N; Rhein S; Werneyer A; Erbel R; Meyer J
Z Kardiol; 1991; 80 Suppl 4():85-91. PubMed ID: 1833903
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the enoximone clinical trials program.
Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
[TBL] [Abstract][Full Text] [Related]
14. Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method.
Installe E; De Coster P; Gonzalez M; Brichant C; Lessire H; Cauwe F
Eur Heart J; 1991 Sep; 12(9):985-93. PubMed ID: 1834466
[TBL] [Abstract][Full Text] [Related]
15. [Tolerance of enoximone in patients with heart failure].
Gilfrich HJ; Dieterich HA
Z Kardiol; 1991; 80 Suppl 4():93-7. PubMed ID: 1833904
[TBL] [Abstract][Full Text] [Related]
16. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Feldman AM; Oren RM; Abraham WT; Boehmer JP; Carson PE; Eichhorn E; Gilbert EM; Kao A; Leier CV; Lowes BD; Mathier MA; McGrew FA; Metra M; Zisman LS; Shakar SF; Krueger SK; Robertson AD; White BG; Gerber MJ; Wold GE; Bristow MR;
Am Heart J; 2007 Nov; 154(5):861-9. PubMed ID: 17967591
[TBL] [Abstract][Full Text] [Related]
17. [Enoximone].
Ventura G
Medicina (Firenze); 1990; 10(2):191-3. PubMed ID: 2148796
[TBL] [Abstract][Full Text] [Related]
18. [Role of the enoximone-dobutamine combination in the treatment of congestive cardiac insufficiency].
Richard C; Thuillez C; Annane D; Bellissant E; Teboul JL
Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():33-7. PubMed ID: 2147832
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of enoximone in chronic heart failure.
Saborowski F; Peters P; Schneider M; Fehske W; Dieterich HA
J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S57-61. PubMed ID: 2480487
[TBL] [Abstract][Full Text] [Related]
20. [Enoximone, vasodilator and/or inotropic agent in congestive cardiac insufficiency? Hemodynamic and ventriculographic study of 20 cases].
Durrieu C; Rochoux G; Coste P; Le Goff G; Besse P
Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():43-50. PubMed ID: 2147834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
